3SBio Stock

3SBio Dividend Coverage

The Dividend Coverage Ratio of 3SBio (1530.HK) as of Aug 21, 2026 is 18.46. In the previous year, Dividend Coverage Ratio was 4.52 — a change of 308.19% (higher).

Dividend Coverage

18.46

YoY

308.19%

Last updated:

Dividend Coverage Ratio of 3SBio is 2026 18.46 . Dividend Coverage Ratio of 3SBio was 2025 4.52 . It decreases by 308.19% higher compared to the previous year.
Access this data via the Eulerpool API

3SBio Stock analysis

What does 3SBio do? 3SBio Inc. is a biopharmaceutical company from China that specializes in the research, development, manufacturing, and marketing of biological products. It was founded in 1993 in Shenyang, a city in northeast China, and its headquarters are now in Beijing. 3SBio's business model is based on the development and manufacturing of biopharmaceuticals that are used to treat cancer, autoimmune diseases, and other serious illnesses. The company focuses on biological medicines such as proteins, antibodies, and peptides that are produced using genetic technology. 3SBio operates a wide range of business sectors, including the manufacturing and sale of biopharmaceutical products, the manufacturing and sale of generics and biosimilar products, and research and development in the biotechnology field. The company also has several subsidiaries and joint ventures, including 3SBio International Holding, Sunshine Guojian Pharmaceutical, and Target Pharma. A well-known product of 3SBio is erythropoietin (EPO), which is used in the treatment of anemia. The company also has a portfolio of other biopharmaceutical products that are used to treat cancer, autoimmune diseases, and other serious illnesses. The history of 3SBio goes back to 1993 when it was founded as Shenyang Sunshine Pharmaceutical. In 2001, the company was renamed "Shenyang Sunshine Pharmaceutical Co. Ltd. 3S Bio" and focused on biological therapy. In 2007, the company successfully listed on the Hong Kong Stock Exchange and received the name 3SBio. In 2013, the company was privatized and acquired by a consortium of Chinese investment companies. 3SBio has a strong presence in China and is also expanding into international markets. The company has distribution partnerships in Asia, Europe, and North America, and plans to enter more markets. Overall, 3SBio is a leading company in China in the field of biopharmaceuticals that focuses on the treatment of serious illnesses. The company aims to be a leader in research and development, as well as in the manufacturing and sale of innovative products, and to expand its presence in global markets. 3SBio is one of the most popular companies on Eulerpool.

Frequently Asked Questions about 3SBio stock

Dividend Coverage Ratio of 3SBio is 18.46 in 2026.

Dividend Coverage Ratio of 3SBio changed from 4.52 to 18.46, representing a 308.19% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Dividend Coverage Ratio 3SBio since 2006 – with annual values, charts, and detailed analysis.

The dividend coverage ratio measures how many times dividends can be covered by net income. Higher coverage suggests more sustainable dividend payments.

Dividend Coverage Ratio's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Dividend Coverage Ratio's 3SBio historically and in real time.

Access this data via the Eulerpool API

Dividend — 3SBio

All Key Metrics — 3SBio